AWM
VRTX icon

Aries Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Aries Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$270K Hold
605
– – 0.06% 197
2025
Q4 		$274K Hold
605
– – 0.06% 193
2025
Q3 		$237K Hold
605
– – 0.06% 207
2025
Q2 		$269K Hold
605
– – 0.07% 193
2025
Q1 		$293K Buy
+605
New +$282K 0.08% 183
2024
Q4 		– Sell
-475
Closed -$221K – 235
2024
Q3 		$221K Hold
475
– – 0.06% 211
2024
Q2 		$223K Buy
+475
New +$206K 0.07% 189

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Aries Wealth Management's VRTX Position: Q1 2026 in Review

Aries Wealth Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 605 shares worth $270K. The position accounts for 0.06% of the portfolio, ranked #197.

Aries Wealth Management first reported a position in VRTX in Q2 2024 and has held it in 7 quarters since. The position peaked at $293K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Aries Wealth Management held 605 shares of Vertex Pharmaceuticals worth $270K as of Q1 2026.
  • Aries Wealth Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
  • Vertex Pharmaceuticals made up 0.06% of Aries Wealth Management's portfolio in Q1 2026, its #197 holding.
  • Aries Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
  • Aries Wealth Management's Vertex Pharmaceuticals position peaked at $293K in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Aries Wealth Management's 13F filing for Q1 2026, filed 15 May 2026.